Marinus Pharmaceuticals Inc’s recent filing unveils that its Director Saraswathy Nochur acquired Company’s shares for reported $3743.0 on Dec 10 ’24. In the deal valued at $0.28 per share,13,250 shares were bought.
Then, Pfanstiel Steven sold 4,657 shares, generating $5,262 in total proceeds. Upon selling the shares at $1.13, the CFO AND COO now owns 79,773 shares.
Before that, Shafer Christina sold 3,820 shares. Marinus Pharmaceuticals Inc shares valued at $4,355 were divested by the CHIEF COMMERCIAL OFFICER at a price of $1.14 per share. As a result of the transaction, Shafer Christina now holds 67,406 shares, worth roughly $36399.240000000005.
Oppenheimer upgraded its Marinus Pharmaceuticals Inc [MRNS] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including Ladenburg Thalmann’s analysts, who decreased its forecast for the stock in mid August from “a Buy” to “a Neutral”. Robert W. Baird also remained covering MRNS and has decreased its forecast on April 16, 2024 with a “Neutral” recommendation from previously “an Outperform” rating. RBC Capital Mkts revised its rating on April 15, 2024. It rated MRNS as “a Sector perform” which previously was an “an Outperform”.
Price Performance Review of MRNS
On Tuesday, Marinus Pharmaceuticals Inc [NASDAQ:MRNS] saw its stock fall -0.39% to $0.54. Over the last five days, the stock has gained 1.01%. Marinus Pharmaceuticals Inc shares have risen nearly 0.73% since the year began. Nevertheless, the stocks have fallen -94.75% over the past one year. While a 52-week high of $10.50 was reached on 01/13/25, a 52-week low of $0.22 was recorded on 01/02/25. SMA at 50 days reached $0.3487, while 200 days put it at $1.5242.
Levels Of Support And Resistance For MRNS Stock
The 24-hour chart illustrates a support level at 0.5360, which if violated will result in even more drops to 0.5331. On the upside, there is a resistance level at 0.5429. A further resistance level may holdings at 0.5469. The Relative Strength Index (RSI) on the 14-day chart is 70.60, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0720, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 5.06%. Stochastics %K at 95.81% indicates the stock is a selling.
How much short interest is there in Marinus Pharmaceuticals Inc?
A steep rise in short interest was recorded in Marinus Pharmaceuticals Inc stocks on 2024-10-31, growing by 2.44 million shares to a total of 5.66 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 3.22 million shares. There was a rise of 43.12%, which implies that there is a positive sentiment for the stock.
